The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.
The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as the base year, 2018 and forecast for 2023.
The Report Includes:
- 21 data tables and 15 additional tables
- Country-specific data and analysis for United States, Canada, Mexico, France, Germany, UK, China, India, Japan, and the Middle East and Africa
- An overview about current and future market potential for antiemetic drugs with special focus on the competitive environment, pipeline drugs and blockbuster drugs
- Coverage of disease burden, regulatory environment, and novel technologies in the antiemetic drugs market
- Detailed description about the vestibular disorder and increasing demand of innovative technology for treatment
- Exploration of the causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting by each application segment
- Information about the launching of new drugs in each antiemetic drug class such as 5 HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonist, and so forth
- Detailed company profiles of major players in the market, including Abbott Laboratories, Daiichi Sankyo Company, Ltd., Merck & Co., Novartis AG, Sanofi Aventis and Teva Pharmaceutical Industries Ltd.
Membership Price:
Contact us for membership pricing.
Table of Contents
Executive Summary
Emesis is a devastating adverse effect of surgery, poisoning, chemotherapy, vestibular imbalance, medication, radiotherapy and during pregnancy. Emesis itself is not a disease but an indication of a stressed physiological condition. During the last decades, extraordinary technological advances have made innovations in most of the disease therapies, including cancer therapies, which is the most common cause of emesis.
The antiemetic drug market is population driven and mostly depends on the number of chemotherapy and radiation therapy sessions performed in specific geographic regions that have high cancer burden and utilize chemotherapy and radiation therapy for cancer treatment. Antiemetics are used to suppress nausea and vomiting associated with CINV, PINV, NVP, RINV, motion sickness and vestibular sickness. 5-HT3 receptor antagonists and NK1 receptor antagonists are the most frequently used antiemetic drug categories.
The 5-HT3 receptor antagonist market accounts for the largest market share of the global antiemetic market. NK1 receptor antagonists are the second largest antiemetic drug segment. Food and Drug Administration(FDA), the commercial launch of new drug candidates, and the existing pipeline which is likely to hit the market in by 2023. Anticholinergics and benzodiazepines are the smallest antiemetic market segments, accounting for approximately REDACTED of the overall market share.
North America is the leading contributor to the antiemetic drug market. The Middle East and Africa antiemetic market are expected to grow at the highest rate during the forecast period.
Companies Mentioned
- Abbott Laboratories
- Aphios Corp.
- Astellas Pharma Inc.
- Aurobindo Pharma
- Daiichi Sankyo Company Ltd.
- Eisai Co., Inc.
- F. Hoffmann-La Roche Ag
- Glaxosmithkline Plc
- Helsinn Healthcare Sa
- Heron Therapeutics, Inc.
- IPCA Laboratories, Ltd.
- Kyowa Hakko Kirin Pharma, Inc.
- Merck & Co., Inc.
- Novartis Ag
- Sanofi Aventis
- Tesaro, Inc.
- Teva Pharmaceutical Industries Ltd.
